Sinopharm Group Co. Ltd Working Capital to Net Assets Ratio
Sinopharm Group Co. Ltd working capital to net assets ratio. Sinopharm Group Co. Ltd (X2S) has a Working Capital to Net Assets ratio of 74.6% as of December 2025. Working capital of €100.07 Billion (current assets of €346.80 Billion minus current liabilities of €246.73 Billion) is measured against net assets of €134.16 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Sinopharm Group Co. Ltd (X2S) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Sinopharm Group Co. Ltd (2013–2025)
Working capital to net assets ratio of Sinopharm Group Co. Ltd from 2013 to 2025. This chart shows how Sinopharm Group Co. Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at 74.6%, reflecting working capital of €100.07 Billion against net assets of €134.16 Billion EUR. See Sinopharm Group Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Sinopharm Group Co. Ltd Working Capital to Net Assets Ratio by Year (2013–2025)
Sinopharm Group Co. Ltd working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Sinopharm Group Co. Ltd from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Sinopharm Group Co. Ltd.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 74.6% | €100.07 Billion | €134.16 Billion | €346.80 Billion | €246.73 Billion | ▼ -2.0 pp |
| 2024 | 76.6% | €97.07 Billion | €126.69 Billion | €347.45 Billion | €250.38 Billion | ▼ -2.6 pp |
| 2023 | 79.2% | €95.34 Billion | €120.32 Billion | €336.84 Billion | €241.49 Billion | ▲ +2.5 pp |
| 2022 | 76.7% | €84.44 Billion | €110.07 Billion | €319.41 Billion | €234.96 Billion | ▲ +4.9 pp |
| 2021 | 71.9% | €71.62 Billion | €99.65 Billion | €290.92 Billion | €219.31 Billion | ▲ +1.1 pp |
| 2020 | 70.7% | €63.63 Billion | €89.95 Billion | €267.61 Billion | €203.98 Billion | ▲ +3.7 pp |
| 2019 | 67.0% | €51.58 Billion | €76.94 Billion | €230.00 Billion | €178.42 Billion | ▲ +1.7 pp |
| 2018 | 65.3% | €44.58 Billion | €68.28 Billion | €204.65 Billion | €160.07 Billion | ▼ -9.2 pp |
| 2017 | 74.5% | €38.19 Billion | €51.27 Billion | €162.77 Billion | €124.58 Billion | ▲ +0.3 pp |
| 2016 | 74.2% | €33.02 Billion | €44.53 Billion | €132.76 Billion | €99.74 Billion | ▲ +19.7 pp |
| 2015 | 54.5% | €22.28 Billion | €40.88 Billion | €117.90 Billion | €95.62 Billion | ▼ -12.3 pp |
| 2014 | 66.8% | €24.25 Billion | €36.29 Billion | €110.27 Billion | €86.02 Billion | ▲ +0.9 pp |
| 2013 | 66.0% | €18.87 Billion | €28.61 Billion | €89.71 Billion | €70.84 Billion | — |